Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Show more authors
+ 1
Laura S Mertens
Jan-Jaap J Mellema
Srikala Sridhar
Michiel S van der Heijden

More about this publication

European urology

Publication date 17-06-2026

Full text links

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.